Watch DNLI. Know when insiders buy.
One email the day a filing lands. Free.
Work order
40
WATCH · insiders 36, shorts 43
Insiders, 90 days
−$327K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.6BP/E —DIV YIELD —FCF YIELD -12.28%REV TTM —NET INCOME −$511.5MNET CASH —52W 12.75 – 27.21SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3.6M | — | 97.4% | −$130.5M | −$127.6M | — | -0.68 | −$97M | $805K | −$97.8M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$137.4M | −$128.4M | — | -0.69 | −$131.2M | $2.5M | −$133.7M | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | −$137.4M | −$128.5M | — | -0.73 | −$98.5M | $1.5M | −$100.1M | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$137.4M | −$126.9M | — | -0.74 | −$107.3M | −$1.4M | −$105.9M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$135M | −$124.1M | — | -0.72 | −$75.3M | $4.3M | −$79.6M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$145.6M | −$133M | — | -0.78 | −$131.5M | $5.1M | −$136.5M | May 7 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$129.8M | −$114.8M | — | -0.68 | −$83.7M | $5.1M | −$88.8M | Feb 26 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$123.2M | −$107.2M | — | -0.63 | −$59.1M | $3.9M | −$63M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$116.6M | −$99M | — | -0.59 | −$91.2M | $4.8M | −$96M | Aug 11 |
| Q1 2024 · Mar 31 | $0 | — | — | −$117.7M | −$101.8M | — | -0.68 | −$113.6M | $2.1M | −$115.8M | May 6 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$132.6M | −$119.5M | — | -0.87 | −$98.7M | $2.2M | −$100.9M | Feb 26 |
| Q3 2023 · Sep 30 | $1.3M | — | — | −$113.8M | −$99.4M | — | -0.72 | −$87.4M | $2.1M | −$89.4M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$555.3M | −$512.5M | — | -2.97 | −$412.6M | $9.5M | −$422.1M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$487.3M | −$422.8M | — | -2.57 | −$347.7M | $15.9M | −$363.6M | — | — |
| FY2023 · to Dec 31 | $330.5M | — | −$196.7M | −$145.2M | -43.9% | -1.06 | −$358M | $12.9M | −$370.9M | — | — |
| FY2022 · to Dec 31 | $108.5M | — | −$340.7M | −$326M | -300.6% | -2.60 | −$244.7M | $17.8M | −$262.5M | — | — |
| FY2021 · to Dec 31 | $48.7M | — | −$295.8M | −$290.6M | -597.2% | -2.39 | −$211.4M | $8.5M | −$219.9M | — | — |
| FY2020 · to Dec 31 | $335.7M | — | $62.7M | $71.1M | 21.2% | 0.63 | $416.2M | $3.1M | $413.1M | — | — |
Every number comes from Denali Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.